news
-
3 November 2020Genkyotex announces the closing of the acquisition by Calliditas Therapeutics of a controlling interest in Genkyotex
Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced the closing of the acquisition by Calliditas Therapeutics AB (“Calliditas”; Nasdaq OMX – CALTX; NASDAQ - CALT) of 62.7% of Genkyotex in an off-market transaction.
On August 13, 2020, Genkyotex announced the agreement by Calliditas to acquire 7,236,515 ordinary shares of Genkyotex, representing 62.7% of the share capital and voting rights from Genkyotex’s largest shareholders and management team (the “Block Sellers”). Having now received clearance from the French Minister of Economy and Finance regarding foreign investments into France, Calliditas has closed today the off-market block trade for a total consideration of €19.75m in cash (€2.73 per ordinary share*) plus contingent rights payable upon regulatory approvals of setanaxib, Genkyotex’s lead asset.
Following the closing of the off-market block trade, the members of the board of directors members other than Mr. Elias Papatheodorou, Chief Executive Officer, have resigned. Mr Elmar Schnee, Chairman of the board of Calliditas, Mrs Renée Aguiar-Lucander, Chief Executive Officer of Calliditas and Mr. Jonathan Schur, Group General Counsel of Calliditas, have been coopted as members of the Board of directors. Mr Elmar Schnee has been elected President of the Board of directors.
Calliditas has announced that it will, in compliance with French and Belgian securities law, file with the French Financial Market Authority (Autorité des Marchés Financiers – the “AMF”) a simplified mandatory cash tender offer for the remaining Genkyotex shares at €2.80 per ordinary share plus contingent right payable upon regulatory approvals of setanaxib. Calliditas indicated that the outcome from the tender offer, if approved by the AMF, is expected to be reported in December and will be followed by a squeezeout of the non-tendered shares under the same terms, if Calliditas then holds more than 90% of the outstanding Genkyotex shares.
* Certain transaction costs (amounting to circa €0.07 per share) have been deducted from the price paid to the Block Sellers.
Related
Genkyotex’s setanaxib granted Orphan Drug Designation by the US FDA for the treatment of PBC
Genkyotex announces first-half 2020 results and business update
Genkyotex Provides Business Update and Reports Cash Position at June 30, 2020
Genkyotex announces the dosing of the first subjects in its Phase 1 study with high-dose setanaxib
Genkyotex Provides Business Update and Reports Cash Position at March 31, 2020
Genkyotex Provides Business Update and Reports Gross Cash Position at December 31, 2019
Genkyotex reports progress of Setanaxib phase 2 investigator initiated trials
Genkyotex provides business update and reports cash position at September 30, 2019
Genkyotex Announces First Half 2019 Results
The Who recognizes Nox Inhibitors as New Therapeutic Class and Approves Setanaxib for GKT831
Genkyotex Announces FDA Approval of Phase 2 InvestigatorInitiated Trial with GKT831 in IPF
Genkyotex’s GKT831 Prevents Multiple Complications of Portal Hypertension in Preclinical Model
Genkyotex Reports Clinical Evidence of Anti-fibrotic Activity by GKT831 in Liver Fibrosis Patients
Genkyotex provides Corporate Update and Reports Cash position at March 31, 2019
Genkyotex Reverse Stock Split Takes Effect
Genkyotex announces 2018 Annual Financial Results and provides Corporate update
Launch of the reverse stock split of Genkyotex shares
Genkyotex provides corporate update and reports cash position at December 31, 2018
Preclinical Efficacy of Genkyotex’s GKT831 in Prostate Cancer Presented at ESUR18 Meeting
Genkyotex provides update on PBC Phase 2 Trial and Reports June 30, 2018, Cash Position
Genkyotex expands License Agreement for Vaxiclase Platform with Serum Institute of India
Genkyotex Announces Leadership Transition
Genkyotex’s NOX1&4 Inhibitor Strategy in Liver Fibrosis Supported by New Preclinical Results